Lancashire and South Cumbria
Formulary
Formulary
9 Nutrition and blood
09-01-03 Drugs used in hypoplastic, haemolytic, and renal anaemias
| Crovalimab Piasky® |
|
Formulary
|
Solution for injection 340mg/2ml Specialist initiation only. |
 NICE TA1019: Crovalimab for treating paroxysmal nocturnal haemoglobinuria in people 12 years and over |
|
| Danicopan |
|
Formulary
|
Tablets 50mg, 100mg
Specialist initiation only. |
|
NICE TA1010: Danicopan with ravulizumab or eculizumab for treating paroxysmal nocturnal haemoglobinuria |
|
|
| Iptacopan Fabhalta® |
|
Formulary
|
Capsules 200mg
Specialist initiation only. |
|
NICE TA1000: Iptacopan for treating paroxysmal nocturnal haemoglobinuria |
|
|
| Ravulizumab Ultomiris® |
|
Formulary
|
Concentrate for solution for infusion 300mg/3mL, 1,100mg/11mL Tertiary centre use only for treating paroxysmal nocturnal haemoglobinuria. Specialist initiation only. |
|
NICE TA698: Ravulizumab for treating paroxysmal nocturnal haemoglobinuria NICE TA710: Ravulizumab for treating atypical haemolytic uraemic syndrome |
|
|
| Rituximab |
|
Formulary
|
Rituximab is recommended as an alternative treatment for adults with autoimmune haemolytic anaemia (AIHA) where patients are contraindicated to or fail to respond to standard active treatments (e.g corticosteroids). Treatment requires initiation and continuation by specialist haematology services. All anti-lymphocyte monoclonal antibodies should be given under the supervision of an experienced specialist, in an environment where full resuscitation facilities are immediately available. |
 LSCMMG: Rituximab Intravenous Infusion for the Treatment of Autoimmune Haemolytic Anaemia (AIHA) in Adults NMR MHRA: Rituximab: screen for hepatitis B virus before treatment |
|
(Unlicensed)| Vadadustat Vafseo® |
|
Formulary
|
Capsules 150mg, 300mg |
|
NICE TA1035: Vadadustat for treating symptomatic anaemia in adults having dialysis for chronic kidney disease |
|
|
Links
- MHRA: Recombinant human erythropoietins: treating anaemia in cancer
- LSCMMG: Bariatric surgery guidelines for prescribing of vitamins and nutritional supplements: Position Statement
- LSCMMG: Gluten-Free food products: Position Statement
- LSCMMG: Oral Nutritional Supplements in Primary Care
- LSCMMG: PKU - Prescribing of Multivitamins & Phenylalanine-free amino acid substitutes for adults and children
- LSCMMG: Rituximab Intravenous Infusion for the Treatment of Autoimmune Haemolytic Anaemia (AIHA) in Adults NMR
- MHRA: Recombinant human erythropoietins: new advice for prescribing
- MHRA: Recombinant human erythropoietins: very rare risk of severe cutaneous adverse reactions (SCARs)
- MHRA: Rituximab: screen for hepatitis B virus before treatment
- NHSE: Clinical Commissioning Policy Treatment of iron overload for transfused and non-transfused patients with chronic inherited anaemias (all ages) (URN 2109) [221004P]
- NHSE: Clinical Commissioning Policy: Treatment of iron overload for transfused and non transfused patients with chronic inherited anaemias
- NICE CG32: Nutrition support for adults: oral nutrition support, enteral tube feeding and parenteral nutrition
- NICE NG20: Coeliac disease: recognition, assessment and management
- NICE NG203: Chronic kidney disease: assessment and management
- NICE TA1000: Iptacopan for treating paroxysmal nocturnal haemoglobinuria
- NICE TA1010: Danicopan with ravulizumab or eculizumab for treating paroxysmal nocturnal haemoglobinuria
- NICE TA1019: Crovalimab for treating paroxysmal nocturnal haemoglobinuria in people 12 years and over
- NICE TA1035: Vadadustat for treating symptomatic anaemia in adults having dialysis for chronic kidney disease
- NICE TA323: Erythropoiesis‑stimulating agents (epoetin and darbepoetin) for treating anaemia in people with cancer having chemotherapy
- NICE TA636: Eculizumab for treating refractory myasthenia gravis (terminated appraisal)
- NICE TA647: Eculizumab for treating relapsing neuromyelitis optica (terminated appraisal)
- NICE TA698: Ravulizumab for treating paroxysmal nocturnal haemoglobinuria
- NICE TA698:Ravulizumab for treating paroxysmal nocturnal haemoglobinuria
- NICE TA710: Ravulizumab for treating atypical haemolytic uraemic syndrome
- NICE TA710: Ravulizumab for treating atypical haemolytic uraemic syndrome
- NICE TA743: Crizanlizumab for preventing sickle cell crises in sickle cell disease
- NICE TA981: Voxelotor for treating haemolytic anaemia caused by sickle cell disease